CoNCERT Pharmaceuticals: ROTH Conference (Concert Pharma) - Mar 11, 2014 - "CTP-499: Potential Effect to Protect Kidney Function"; "Trial results did not achieve primary 24 week UACR endpoint: Urinary albumin has fallen out of favor in past several years as an endpoint; Several recent studies demonstrated that decreasing UACR beyond an AECi or ARB did not result in additional protection of kidney function"
P2 data • Renal Disease
|